Lombard Odier Asset Management (Usa) Corp Bristol Myers Squibb CO Call Options Transaction History

Lombard Odier Asset Management (Usa) Corp

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$40.25 - $52.99 $12.1 Million - $15.9 Million	300,000 Added 200.0%	450,000 $18.7 Million
Q1 2024 May 15, 2024	BUY	$47.98 - $54.4 $7.2 Million - $8.16 Million	150,000 New	150,000 $8.13 Million
Q1 2022 May 16, 2022	SELL	$61.48 - $73.72 $2.77 Million - $3.32 Million	-45,000 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$53.63 - $62.52 $1.21 Million - $1.41 Million	-22,500 Reduced 33.33%	45,000 $2.81 Million
Q3 2021 Nov 12, 2021	BUY	$59.17 - $69.31 $3.99 Million - $4.68 Million	67,500 New	67,500 $3.99 Million
Q2 2019 Aug 14, 2019	SELL	$44.62 - $49.34 $4.37 Million - $4.84 Million	-98,000 Closed	0 $0
Q1 2019 May 16, 2019	BUY	$45.12 - $53.8 $2.48 Million - $2.96 Million	55,000 Added 127.91%	98,000 $4.68 Million
Q1 2019 May 15, 2019	BUY	$45.12 - $53.8 $1.94 Million - $2.31 Million	43,000 New	43,000 $4.68 Million

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Lombard Odier Asset Management (Usa) Corp, based on Form 13F filings with the SEC.

Stay updated on Lombard Odier Asset Management (Usa) Corp with notifications on news.